914612-23-0

Basic information

• Product Name: 6-BENZYL-4-CHLORO-5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE
• Synonyms: 6-BENZYL-4-CHLORO-5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE;CIVENTICHEM CV-5309;6-Benzyl-4-chloro-5,6,7,8...;6-benzyl-4-chloro-5;6-benzyl-4-chloro-5H,6H,7H,8H-pyrido[4,3-d]pyriMidine;-BENZYL-4-CHLORO-5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE
• CAS NO: 914612-23-0
• Molecular Formula: C₁₄H₁₄ClN₃
• Molecular Weight: 259.73
• Product Categories: pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 914612-23-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 396.568 °C at 760 mmHg
• Flash Point: 193.638 °C
• Appearance: /
• Density: 1.273 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 5.01±0.20(Predicted)
• CAS DataBase Reference: 6-BENZYL-4-CHLORO-5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BENZYL-4-CHLORO-5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE(914612-23-0)
• EPA Substance Registry System: 6-BENZYL-4-CHLORO-5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE(914612-23-0)

Safety Data

• Hazardous Substances Data: 914612-23-0(Hazardous Substances Data)

Usage

General Description

6-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine is a chemical compound with the molecular formula C15H16ClN3. It is a heterocyclic compound that contains a pyrimidine ring fused to a tetrahydropyridine ring. 6-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine is of interest due to its potential pharmacological properties, including its possible activity as a ligand for various biological receptors or enzymes. Its structure suggests that it may have relevance for drug development and medicinal chemistry, as it contains both a pyrimidine and a tetrahydropyridine moiety, which are commonly found in biologically active compounds. Further research may be warranted to explore its potential applications in the pharmaceutical industry.

InChI:InChI=1/C14H14ClN3/c15-14-12-9-18(7-6-13(12)16-10-17-14)8-11-4-2-1-3-5-11/h1-5,10H,6-9H2

Upstream product

• 109229-22-3 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one 
• 57611-47-9 1-benzyl-4-oxo-piperidine-3-carboxylic acid methyl ester 
• 1454-53-1 ethyl 1-benzyl-4-oxopiperidine-3-carboxylate hydrochloride 

Downstream Products

• 1332455-18-1 C₂₂H₂₈N₄O₂ 
• 1332455-28-3 biphenyl-4-yl{4-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl}methanone 
• 1332454-53-1 C₂₃H₂₅BrN₄O₂ 
• 1332453-13-0 4'-({4-[4-(cyclopropylcarbonyl)piperidin-1-yl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl}carbonyl)-3-fluorobiphenyl-2-carbonitrile 
• 1332453-16-3 cyclopropyl(l-{6-[(4'-fluorobiphenyl-4-yl)carbonyl]-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl}piperidin-4-yl)methanone 
• 1332455-30-7 ethyl 1-(6-(4-chlorophenylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)piperidine-4-carboxylate 
• 1332455-36-3 C₂₃H₂₈N₄O 
• 1354691-91-0 3-(6-benzyl-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yloxy)-azetidine-1-carboxylic acid tert-butyl ester 
• 1354691-71-6 (S)-3-(6-benzyl-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1354691-53-4 (S)-3-(6-benzyl-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yloxy)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1354691-94-3 6-benzyl-4-((S)-pyrrolidin-3-yloxy)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidine 
• 1354690-24-6 1-[(3S)-3-({5,6,7,8-tetrahydro-6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]pyrido[4,3-d]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one 
• 1354691-99-8 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one hippurate 
• 1354691-96-5 1-[(S)-3-(6-benzyl-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yloxy)-pyrrolidin-1-yl]-propan-1-one 

Relevant articles and documents

Design of A Metabolically Stable Tritium-Tracer of the PI3Kδ-Inhibitor CDZ173 (Leniolisib) as a Tool to Study Liver Metabolites

In this disclosure, we summarize the preliminary metabolic profiling of the PI3Kδ inhibitor CDZ173 (leniolisib, 1a) obtained from incubations of the unlabeled compound and the synthesis of its metabolically stable tritium isotopologue 1b used for metaboli

TASK CHANNEL ANTAGONISTS

This invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders

PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF

Fused heterocyclic compounds are provided according to formula 1a or 1b: where R1, R2, and R3 are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.